Evogene Beats Q2 EPS Estimates, Misses Revenue Target by $0.05M

Evogene reported Q2 GAAP EPS of -$0.50, beating consensus by $0.13. Revenue of $0.88M increased 44.3% YoY, but missed expectations by $0.05M.

Evogene Ltd. (NASDAQ: EVGN) reported its Q2 GAAP EPS of -$0.50, beating the consensus estimate of -$0.63 by $0.13. The company's revenue totaled $0.88M, representing a 44.3% year-over-year (YoY) increase, but it missed the consensus revenue estimate of $0.93M by $0.05M [1].

According to the company's earnings call transcript, Evogene's EPS of -$0.50 was a significant improvement from the -$0.85 reported in the previous quarter. The revenue of $0.88M marked a notable increase from the $0.60M reported in the same period last year. However, the company's revenue fell short of market expectations by $0.05M [1].

Over the past two years, Evogene has consistently exceeded EPS estimates 75% of the time and revenue estimates 63% of the time. This quarter's results, while not meeting revenue expectations, still indicate a strong performance in terms of EPS, which was significantly above the consensus estimate [2].

Investors should closely monitor Evogene's earnings call scheduled for Tuesday, August 19th, before market open, for further insights into the company's financial performance and future prospects.

References:
[1] https://seekingalpha.com/news/4486882-evogene-gaap-eps-of-0_85-misses-by-0_22-revenue-of-0_88m-misses-by-0_05m
[2] https://seekingalpha.com/news/4486643-evogene-q2-2025-earnings-preview